Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 14/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25302389 | 0.79 | CYP1A2 (0.45) | AHRCYP1A2PDGFRAFERLTK | |
| SCHEMBL732391 | 0.78 | ALDH1A1 (0.44) | AHRJAK2CYP1A2ACVR1GSK3B | |
| SCHEMBL29610334 | 0.75 | PARP1 (0.46) | CYP1A2PDGFRAFERLTKCDK8 | |
| SCHEMBL18624461 | 0.74 | AHR (0.41) | AHRJAK2PDGFRAFERLTK | |
| SCHEMBL18624248 | 0.74 | JAK2 (0.40) | AHRJAK2CYP1A2PDGFRAFER | |
| SCHEMBL18624250 | 0.74 | AHR (0.49) | AHRJAK2CYP1A2PDGFRAFER | |
| SCHEMBL5044997 | 0.73 | AHR (0.49) | AHRJAK2MDM2ACVR1LRRK2 | |
| SCHEMBL22335167 | 0.73 | PDPK1 (0.41) | AHRCYP1A2CDK5CDK5R1MAPT | |
| SCHEMBL17402501 | 0.72 | ALDH1A1 (0.54) | AHRPDGFRAFERLTKCDK8 | |
| SCHEMBL9386045 | 0.71 | AHR (0.47) | AHRJAK2MDM2PDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994003433-A1 | BIOLOGICAL APPLICATIONS OF ALKALOIDS DERIVED FROM THE TUNICATE EUDISTOMA sp. | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-02-17 | — | — | WO | claimed |
| EP-3573985-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2023-01-18 | — | — | EP | disclosed |
| WO-2018138306-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-6525063-B2 | 3,7-dimethyl-1,5-diazaanthraquinone for example | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2003-02-25 | — | — | US | disclosed |
| US-20020128281-A1 | Cytotoxic compounds: derivatives of the pyrido [2,3,4-kl]acridine ring system | UNIVERSIDAD COMPLUTENSE DE MADRID | 2002-09-12 | — | — | US | disclosed |
| US-20020099066-A1 | Antitumour 1,5-diazaanthraquinones | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-07-25 | — | — | US | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-5432172-A | Biological applications of alkaloids derived from the tunicate Eudistoma sp. | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-07-11 | — | — | US | disclosed |
| US-5432172-A | Biological applications of alkaloids derived from the tunicate Eudistoma sp. | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-07-11 | — | — | US | disclosed |
| WO-1994003433-A1 | BIOLOGICAL APPLICATIONS OF ALKALOIDS DERIVED FROM THE TUNICATE EUDISTOMA sp. | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1994003433-A1 | BIOLOGICAL APPLICATIONS OF ALKALOIDS DERIVED FROM THE TUNICATE EUDISTOMA sp. | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5278168-A | Biological applications of alkaloids derived from the tunicate Eudistoma sp. | THE RESEARCH FOUNDATION OF STATE UNIVERISTY OF NEW YORK (US) | 1994-01-11 | — | — | US | disclosed |
| US-5278168-A | Biological applications of alkaloids derived from the tunicate Eudistoma sp. | THE RESEARCH FOUNDATION OF STATE UNIVERISTY OF NEW YORK (US) | 1994-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | AHR 3307/4885JAK2 854/4885CYP1A2 4314/4885 |
| US-20020099066-A1 | Antitumour 1,5-diazaanthraquinones | PRMT7, TPD52L2, DRD4 | AHR 427/4885JAK2 1761/4885CYP1A2 2967/4885 |
| US-20020128281-A1 | Cytotoxic compounds: derivatives of the pyrido [2,3,4-kl]acridine ring system | CASP3, NR4A1, CASP4 | AHR 128/4885JAK2 4443/4885CYP1A2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.